Gut microbiota modulate distal symmetric polyneuropathy in patients with diabetes

Discussion in ''Conditions related to ME/CFS' news and research' started by Joan Crawford, Aug 21, 2023.

  1. Joan Crawford

    Joan Crawford Senior Member (Voting Rights)

    Messages:
    630
    Location:
    Warton, Carnforth, Lancs, UK
    Thought this was an interesting small study.

    Gut microbiota modulate distal symmetric polyneuropathy in patients with diabetes

    Junpeng Yang 7
    Xueli Yang 7
    Guojun Wu 7
    Faming Zhang
    Chenhong Zhang
    Huijuan Yuan 8

    Open Access Published:July 13, 2023

    DOI:https://doi.org/10.1016/j.cmet.2023.06.010

    Highlights

    Gut microbiota from patients with DSPN induce severe peripheral neuropathy in db/db mice

    In a randomized clinical trial, FMT from healthy donors significantly alleviated DSPN

    Two competing guilds of gut microbiota were associated with FMT-induced alleviation of DSPN

    Matched enterotype between transplants and recipients linked to better FMT efficacy

    Summary
    The pathogenic mechanisms underlying distal symmetric polyneuropathy (DSPN), a common neuropathy in patients with diabetes mellitus (DM), are not fully understood. Here, we discover that the gut microbiota from patients with DSPN can induce a phenotype exhibiting more severe peripheral neuropathy in db/db mice. In a randomized, double-blind, and placebo-controlled trial (ChiCTR1800017257), compared to 10 patients who received placebo, DSPN was significantly alleviated in the 22 patients who received fecal microbiota transplants from healthy donors, independent of glycemic control. The gut bacterial genomes that correlated with the Toronto Clinical Scoring System (TCSS) score were organized in two competing guilds. Increased guild 1, which had higher capacity in butyrate production, and decreased guild 2, which harbored more genes in synthetic pathway of endotoxin, were associated with improved gut barrier integrity and decreased proinflammatory cytokine levels. Moreover, matched enterotype between transplants and recipients showed better therapeutic efficacy with more enriched guild 1 and suppressed guild 2. Thus, changes in these two competing guilds may play a causative role in DSPN and have the potential for therapeutic targeting.

    https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00220-6

    Saw this study mentioned in New Scientist:
    https://www.newscientist.com/articl...betes-can-be-treated-with-faecal-transplants/
     
    shak8 and DokaGirl like this.

Share This Page